Analyst Price Targets — NVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 12:09 pm | Thibault Boutherin | Morgan Stanley | $170.00 | $149.70 | TheFly | Novartis price target raised to $170 from $143 at Morgan Stanley |
| December 10, 2025 11:16 am | — | HSBC | $112.00 | $131.01 | TheFly | Novartis price target raised to $112 from $106 at HSBC |
| December 3, 2025 11:33 am | — | Morgan Stanley | $143.00 | $132.28 | TheFly | Novartis price target raised to $143 from $136 at Morgan Stanley |
| October 29, 2025 3:42 pm | Wan Nurhayati | CFRA | $126.00 | $123.33 | StreetInsider | Novartis (NVS) PT Raised to $126 at CFRA |
| October 30, 2024 8:48 am | Etzer Darout | BMO Capital | $120.00 | $109.91 | StreetInsider | Novartis (NVS) PT Raised to $120 at BMO Capital |
| September 5, 2024 4:27 am | James Quigley | Goldman Sachs | $121.00 | $119.38 | TheFly | Novartis downgraded to Neutral from Buy at Goldman Sachs |
| July 19, 2024 9:06 am | Etzer Darout | BMO Capital | $118.00 | $106.13 | StreetInsider | Novartis (NVS) PT Raised to $118 at BMO Capital |
| April 23, 2024 1:11 pm | Wan Nurhayati | CFRA | $108.00 | $97.27 | StreetInsider | Novartis (NVS) PT Raised to $108 at CFRA |
Latest News for NVS
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Farther Finance Advisors LLC raised its holdings in Novartis AG (NYSE: NVS) by 87.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,378 shares of the company's stock after purchasing an additional 16,069 shares during the quarter. Farther Finance Advisors
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.
Novartis AG (NYSE: NVS - Get Free Report) has received a consensus rating of "Hold" from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and one has given a
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVS.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.